Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) reported results for the quarter ended March 31, 2026, highlighting an FDA agreement on a single adaptive Phase 2/3 study for Gemini and presentation of additional PRIME Study data at AKI & CRRT 2026. Cash and proceeds totaled $14.1M, including $6.7M from a January warrant inducement. Net cash used in operations was $3.2M and net loss was $3.0M ($2.71 per share). The company believes current resources fund operations through Q1 2027.
Positive
- FDA agreed on a single adaptive Phase 2/3 study pathway for Gemini
- Received $6.7M net proceeds from January 2026 warrant inducement
- Cash and cash equivalents of $14.1M as of March 31, 2026
- Presented additional PRIME Study data at AKI & CRRT 2026
Negative
- Net loss of $3.0M for Q1 2026, larger than Q1 2025 net loss of $2.1M
- Net cash used in operating activities increased to $3.2M from $2.8M
- Cash runway stated only through Q1 2027 under current plans
News Market Reaction – REVB
In the May 8 session, REVB declined 5.88%, reflecting a notable negative market reaction. Trading volume was elevated at 2.9x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings and update | Positive | -0.8% | Year-end 2025 results with $10.7M cash and Gemini progress plus runway. |
| Nov 06 | Quarterly earnings | Positive | -2.9% | Q3 2025 results, PRIME topline data, warrant inducement and higher cash. |
| Aug 08 | Quarterly earnings | Negative | -6.7% | Q2 2025 results showing cash decline and ongoing net losses despite financing. |
| May 08 | Quarterly earnings | Negative | +2.7% | Q1 2025 results with lower cash, continued net loss and Gemini updates. |
| Mar 06 | Annual earnings | Negative | +0.9% | Full-year 2024 loss of $15.0M, cash decline and higher operating cash use. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have typically produced modestly negative reactions, with 4 of 5 tagged events moving down and only one showing alignment between negative fundamentals and a price drop.
Over the last year, Revelation’s earnings updates have consistently paired financial results with Gemini development milestones. Prior reports highlighted cash balances between $3.7M and $12.7M, repeated use of warrant inducements and offerings, and net losses ranging from $1.7M to $15.0M on an annual basis. Market reactions to these earnings headlines were mostly negative, even when cash runway improved or clinical progress was reported. Today’s Q1 2026 update, with higher cash and a runway into Q1 2027, fits this pattern of financial updates intertwined with Gemini progress.
Key Terms
phase 2/3 medical
acute kidney injury medical
warrant inducement financial
clinical research organizations medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026.
Corporate Highlights
Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury
Received net proceeds of
$6.7 million from warrant inducement in January 2026Participated in a fireside chat at the 38th Annual ROTH Conference, during which management discussed the Company's developments and strategic priorities
Presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026)
Initiated discussions with potential clinical research organizations for the single adaptive Phase 2/3 study
"The incredible momentum achieved in 2025 is continuing in 2026," said James Rolke, Chief Executive Officer of Revelation. "Our focus remains on getting our pivotal clinical study of Gemini in acute kidney patients underway for the benefit of those patients and ultimately to deliver significant value for our shareholders."
Results of Operations
As of March 31, 2026, Revelation had
Net cash used for operating activities for the three months ended March 31, 2026 was
About Gemini
Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEM-AKI); Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI), and as a treatment to prevent post-surgical infection (GEM-PSI). The potential of Gemini to correct dysregulated inflammation has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two Phase 1 clinical studies. See additional detail here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth, profitability, and retain its key employees; the possibility that Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such studies are positive or whether they can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
REVELATION BIOSCIENCES, INC.
Consolidated Statements of Operations
Three Months Ended | ||||||||
2026 | 2025 | |||||||
Operating expenses: | ||||||||
Research and development | $ | 1,376,861 | $ | 858,830 | ||||
General and administrative | 1,715,639 | 1,236,157 | ||||||
Total operating expenses | 3,092,500 | 2,094,987 | ||||||
Loss from operations | (3,092,500 | ) | (2,094,987 | ) | ||||
Other income (expense): | ||||||||
Change in fair value of warrant liability | - | 1,417 | ||||||
Other income (expense), net | 83,449 | 42,485 | ||||||
Total other income (expense), net | 83,449 | 43,902 | ||||||
Net loss | $ | (3,009,051 | ) | $ | (2,051,085 | ) | ||
Deemed dividends | (5,681,616 | ) | - | |||||
Net loss attributable to common stockholders | (8,690,667 | ) | (2,051,085 | ) | ||||
Net loss per share, basic and diluted | $ | (2.71 | ) | $ | (25.34 | ) | ||
Weighted-average shares used to compute net loss per share, basic and diluted | 3,207,720 | 80,943 | ||||||
REVELATION BIOSCIENCES, INC.
Consolidated Balance Sheets
March 31, | December 31, | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 14,113,415 | $ | 10,700,331 | ||||
Prepaid expenses and other current assets | 92,620 | 111,297 | ||||||
Total current assets | 14,206,035 | 10,811,628 | ||||||
Property and equipment, net | 140,717 | 18,067 | ||||||
Operating lease right-of-use asset | 666,589 | 722,288 | ||||||
Other assets | 30,941 | 30,941 | ||||||
Total assets | $ | 15,044,282 | $ | 11,582,924 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 828,203 | $ | 577,501 | ||||
Accrued expenses | 468,082 | 1,397,644 | ||||||
Operating lease liability | 120,861 | 23,013 | ||||||
Total current liabilities | 1,417,146 | 1,998,158 | ||||||
Operating lease liability, net of current portion | 638,183 | 723,771 | ||||||
Total liabilities | 2,055,329 | 2,721,929 | ||||||
Commitments and Contingencies (Note 4) | ||||||||
Stockholders' equity: | ||||||||
Common Stock, | 3,908 | 1,584 | ||||||
Additional paid-in-capital | 65,413,383 | 58,278,698 | ||||||
Accumulated deficit | (52,428,338 | ) | (49,419,287 | ) | ||||
Total stockholders' equity | 12,988,953 | 8,860,995 | ||||||
Total liabilities and stockholders' equity | $ | 15,044,282 | $ | 11,582,924 | ||||
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire